Case Report: Should Regorafenib be prescribed as a continuous schedule in gastrointestinal stromal tumors? Three case reports on Regorafenib personalized schedule

IntroductionRegorafenib is a tyrosine kinase inhibitor (TKI) approved in metastatic gastrointestinal stromal tumor (GIST), colorectal cancer, and hepatocarcinoma. Anyway, the toxicity profile of Regorafenib standard schedule is associated with poor compliance and a high rate of discontinuation. For...

Full description

Bibliographic Details

Published in:	Frontiers in Oncology
Main Authors:	Maria Susanna Grimaudo, Alice Laffi, Nicolò Gennaro, Roberta Fazio, Federico D’Orazio, Laura Samà, Licia Vanessa Siracusano, Federico Sicoli, Salvatore Lorenzo Renne, Armando Santoro, Alexia Francesca Bertuzzi
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-05-01
Subjects:	Regorafenib sarcoma GIST case report personalized therapy
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2023.1190123/full